News
GSK plc has entered into agreements with China-based biotechnology company Hengrui Pharma to develop up to 12 innovative ...
Amid plans to transfer manufacturing for an investigational vaccine to a souped-up plant in Pennsylvania, GSK is parting ways ...
Co-founder and CEO Jareeporn Jarukornsakul built industrial parks developer WHA from the ground up. Now she's facing the ...
GSK is acquiring an experimental medicine from a Cambridge biotech to shore up its drug pipeline and muscle into the promising field of liver therapies.
We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where GSK plc (NYSE: GSK) stands against other ...
GSK already has six manufacturing sites in the US, including an $800mn investment under construction in Pennsylvania that was announced last year.
After calling Rockville, Maryland, home for more than eight years, GSK's vaccine and infectious disease R&D teams are planning a move northeast to Cambridge, Massachusetts, the company confirmed ...
GSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio.
GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-bas ...
Following outlays for sites in the UK and Belgium earlier this year, GSK is planning to invest up to $800m in the US to double the size and capacity of its site in Marietta, Pennsylvania.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results